Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2008
11/25/2008US7456157 Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus
11/25/2008US7456156 Aryl boronic acids for treating obesity
11/25/2008US7456155 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
11/25/2008US7456154 Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof
11/25/2008US7456015 Nervous system disorder; includes a first nucleic acid, a second nucleic acid, inverted terminal repeats of adeno-associated virus, and a tetracycline-off regulatable promoter system; tightly regulatable gene delivery vector
11/25/2008US7455986 Heparinase III and methods of specifically cleaving therewith
11/25/2008US7455864 controlled and sustained release capsules containing melatonin, theanine, lavender flower and Ferula plant extracts
11/25/2008US7455857 Energy generating composition
11/25/2008US7455856 Lipid-derivatized bisphosphonic acid
11/25/2008US7455840 Inhibition of drug resistance to quinolone antibiotics by administering to the bacteria a quinolone and an agent that inhibits LexA, thereby inhibiting an SOS response pathway in the bacteria e.g. dipeptide Ala-Ala, alanylalanine or the gene/proteins PsiB, DinI
11/25/2008US7455836 Administering an agent which antagonizes the effects of a colony stimulating factor on these monocyte/macrophage cells to lower levels or reduce their activity; treating inflammation
11/25/2008US7455698 4-(Pyrazol-4-ylimino)-2,5-cyclohexadienylidene quaternary ammonium salts; oxidation color dyes, pyrazole dyes, and hair dyes; intense blue; colorfastness, washfastness, storage stability, water solubility
11/25/2008CA2590111A1 Tocopherol derivatives and uses thereof
11/25/2008CA2449922C Pharmaceutical composition for therapy of interstitial cystitis
11/25/2008CA2433878C Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
11/25/2008CA2421254C Methods for treating tumors using sulfonyl compounds
11/25/2008CA2414146C Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness
11/25/2008CA2383212C Controlled release oral dosage suitable for oral administration
11/25/2008CA2382588C Polymorphs of n-methyl-n-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-.alpha.]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
11/25/2008CA2380766C Calcium complex of phosphorus containing diethylenetriamine derivatives
11/25/2008CA2376791C Drug delivery device for insertion in the vagina, rectum or nasal cavity
11/25/2008CA2376760C Quinolinecarboxylic acid derivative or salts thereof
11/25/2008CA2375549C Delivery system for biological material
11/25/2008CA2375364C Process for preparing 6-o-alkenyl-substituted erythromycin derivatives
11/25/2008CA2370565C Dermally applicable vitamin d-containing pharmaceutical compositions
11/25/2008CA2367666C Method of treating eating disorders
11/25/2008CA2362211C Benzamide derivatives and medicament containing the same
11/25/2008CA2361318C Novel nucleosides and oligonucleotide analogues
11/25/2008CA2348390C Compositions for the treatment and prevention of neurological and pathopsychological diseases
11/25/2008CA2345354C Antisense modulation of bcl-x expression
11/25/2008CA2342830C 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
11/25/2008CA2322689C Substituted bisindolymaleimides for the inhibition of cell proliferation
11/25/2008CA2320182C Compositions containing organic compounds
11/25/2008CA2318579C Nitrogen-containing heterocyclic compounds and medicaments containing the compounds
11/25/2008CA2276606C Method of treating prostatic diseases using active vitamin d analogues
11/25/2008CA2271136C Novel pyridonecarboxylic acid derivatives or salts thereof and drugs containing the same as the active ingredient
11/25/2008CA2264776C Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity
11/25/2008CA2256977C Methods of extended use oral contraception
11/25/2008CA2224369C Aromatic acid diamides with antigastrin activity, a method for their preparation and their pharmaceutical use
11/25/2008CA2221418C Insecticidal combination effective against fleas on mammals, particularly cats and dogs
11/25/2008CA2219747C Aminothiazole derivative, medicament containing the same, and intermediate for preparation of said compound
11/25/2008CA2204406C Lipid metabolism improving agent
11/23/2008CA2688897A1 Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure
11/23/2008CA2590048A1 Cytosine nucleoside analogs and isoflavones and uses thereof
11/21/2008CA2685967A1 Csf-1r inhibitors, compositions, and methods of use
11/20/2008WO2008141312A1 ((phenyl)imidazolyl)methylheteroaryl compounds
11/20/2008WO2008141276A1 Anti-alpha-v immunoliposome composition, methods and uses
11/20/2008WO2008141249A1 Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
11/20/2008WO2008141239A1 Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors
11/20/2008WO2008141227A1 Novel peptide inhibitors of hepatitis c virus replication
11/20/2008WO2008141189A1 Ghrelin modulating compounds and combinations thereof
11/20/2008WO2008141176A1 Methods of treatment of skin ulcers
11/20/2008WO2008141145A1 Condensed heterocyclic compounds as inhibitors of protein kinases
11/20/2008WO2008141140A1 Condensed heterocyclic compounds as inhibitors of protein kinases
11/20/2008WO2008141135A1 Novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives
11/20/2008WO2008141129A1 G-QUARTET OLIGONUCLEOTIDES THAT TARGET HYPOXIA-INDUCIBLE FACTOR 1-α (HIF1 α)
11/20/2008WO2008141119A2 Modulators of cftr
11/20/2008WO2008141114A1 Use of hdac inhibitors for the treatment of melanoma
11/20/2008WO2008141112A1 Methods of treating rett syndrome
11/20/2008WO2008141097A2 Stereoisomers propofol therapeutic compounds
11/20/2008WO2008141082A1 Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
11/20/2008WO2008141081A1 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
11/20/2008WO2008141079A1 Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer
11/20/2008WO2008141077A1 Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives
11/20/2008WO2008141065A1 Quinoxaline derivatives as p13 kinase inhibitors
11/20/2008WO2008141057A1 Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
11/20/2008WO2008141040A2 Use of n-acetylcysteine for inhibition of uv-induced skin cancer
11/20/2008WO2008141033A1 Substituted naphthalenes
11/20/2008WO2008141021A1 Deuterated derivatives of tetrahydrotriazolopyrazine compounds and their use as dpp-iv inhibitors
11/20/2008WO2008141020A1 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists
11/20/2008WO2008141013A1 S1p3 receptor inhibitors for treating pain
11/20/2008WO2008141012A2 Quaternary alkyl ammonium bacterial efflux pump inhibitors and therapeutic uses thereof
11/20/2008WO2008140947A1 P70 s6 kinase inhibitors
11/20/2008WO2008140895A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
11/20/2008WO2008140872A1 A delivery system and method to delivery homeopathic complexes comprising homeopathic colored pigment products for cosmetic use
11/20/2008WO2008140850A1 Solid forms of a raf kinase inhibitor
11/20/2008WO2008140828A1 Inhibitors of acetyl-coa carboxylase for treatment of neuronal hypometabolism
11/20/2008WO2008140810A1 Certain chemical entities, compositions, and methods
11/20/2008WO2008140792A1 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
11/20/2008WO2008140781A1 Spiro compounds for treatment of inflammatory disorders
11/20/2008WO2008140772A2 Robust rapid disintegration tablet formulation
11/20/2008WO2008140750A1 Compounds for modulating trpv3 function
11/20/2008WO2008140724A1 Methods of treatment using intravenous formulations comprising temozolomide
11/20/2008WO2008140713A1 Methods and products for treating proliferative disorders
11/20/2008WO2008140708A1 Use of hdac inhibitors for treatment of cardiac rhythm disorders
11/20/2008WO2008140574A2 Radiation protection and treatment for exposure to gamma-radiation
11/20/2008WO2008140549A1 P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-β-D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D] PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION
11/20/2008WO2008140507A2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
11/20/2008WO2008140500A2 Hyaluronidase inhibitors as anti-cancer agents
11/20/2008WO2008140499A2 Method for treating sepsis
11/20/2008WO2008140448A1 5-htp combination therapy
11/20/2008WO2008140440A1 Stable flavonoid solutions
11/20/2008WO2008140421A2 Heterocycloalkyl substituted pyrimidine derivatives
11/20/2008WO2008140420A2 Pyrimidine derivatives
11/20/2008WO2008140419A2 Pyridyl substituted pyrimidine derivatives
11/20/2008WO2008140373A1 A liquid formulation for administering nicotine
11/20/2008WO2008140372A1 Coated oral nicotine formulation buffered with amino acid
11/20/2008WO2008140371A1 Oral nicotine formulation buffered with amino acid
11/20/2008WO2008140335A2 Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
11/20/2008WO2008140302A1 Polymorphic forms of tenofovir disoproxil fumarate
1 ... 2983 2984 2985 2986 2987 2988 2989 2990 2991 2992 2993 2994 2995 2996 2997 2998 2999 3000 3001 3002 3003 ... 7860